James O'Brien
ID DEMO-005Critical Review PriorityLatest assessment 2026-06-14T00:42:40.359003+00:00Messages →Report →Export summary →Decision support only. Consolidates patient data for faster physician review. It does not diagnose, recommend treatment, generate dosing, or replace physician judgment.
Primary phenotype
immune dysregulation
Recovery stage
improving
Confidence
70/100
moderate
Clinical improvement
56
functional 54
Phenotype profile
Clinical snapshot
immune dysregulation70%mold cirs pattern
Recovery stage (derived): improving — Clinical improvement score 56 (56–69 vs baseline).
Top contributors: Flushing / hives (mast cell activation), Chemical / scent sensitivity, New or worsening allergies, Recurrent infections, Swollen lymph nodes
Phenotype engine
All phenotype scores
Co-infection engine
Pattern scores
bartonella0 Low
babesia0 Low
ebv0 Low
mold cirs17 Low
mcas89 High
Lab intelligence
System concern scores
inflammatory0 Low
immune40 Mild
mitochondrial0 Low
hormonal0 Low
metabolic0 Low
nutritional0 Low
detoxification0 Low
neuroinflammatory0 Low
connective tissue0 Low
Abnormal: eosinophils (high) · Missing: 42
Safety review
Risk flags
critical
reaction history
Anaphylaxis history is a critical reaction-risk consideration.
high
reaction history
High-reactivity or severe flare history may increase risk of intolerance.
high
reaction history
MCAS/high-reactivity history may increase risk of intolerance.
Monitoring: Allergy and reaction history review, Physician review before protocol selection
Missing: allergy_history_confirmed, pregnancy_status_confirmed, infection_status_confirmed
Outcomes
Baseline vs current
| Metric | Baseline | Current |
|---|---|---|
| fatigue score | 6 | 5 |
| brain fog score | — | — |
| pain score | 4 | 3 |
| sleep quality score | 4 | 5 |
| pem score | — | — |
| work capacity percent | 45 | 55 |
Knowledge
Phenotype-relevant references
Protocol assets: BPC-157TB-500 / TB4KPVLL-37MOTS-cSS-31GHK-CuIpamorelinCJC-1295
Evidence documents: EBV Reactivation: Background (observational)Long COVID (PASC): Background (observational)Synergistic Effects of Monolaurin, Thymosin Alpha-1, KPV, SS-31, MOTS-c, Zinc, Vitamin D3, B12, Folate, Selenium, Magnesium Glycinate, and DGL on Epstein-Barr Virus Reversal in a Murine Gammaherpesvirus 68 (MHV-68) Model.docx (expert_opinion)Synergistic Effects of Thymosin Alpha-1, BPC-157, TB-500, LL-37, MOTS-c, SS-31, CJC-1295 with DAC, Ipamorelin, and Nicotine on Lyme Disease Reversal in a Borrelia burgdorferi-Infected Murine Model.docx (expert_opinion)Copy of Synergistic Effects of Monolaurin, Thymosin Alpha-1, KPV, SS-31, MOTS-c, Zinc, Vitamin D3, B12, Folate, Selenium, Magnesium Glycinate, and DGL on Epstein-Barr Virus Reversal in a Murine Gammaherpesvirus 68 (MHV-68) Model.docx (expert_opinion)
Dosing references are provider-only and shown in the asset evidence / protocol context, never patient-facing.
Protocol builder
Protocol plans
Provider workspace
Review & notes
Current status: reviewed